Pharmaxis Ltd (ASX:PXS) is an Australian pharmaceutical research company with expertise in developing drugs for inflammatory and fibrotic diseases and focussed on myelofibrosis.
The company expects to announce receipt of milestone payments and the start of sales from its Bronchitol treatment in the near-term.
Mid caps
Pharmaxis CEO says US FDA approval for Bronchitol® is 'big day in company's history'
Director Interviews
Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020
